AbbVie Inc. EV/EBITDA

EV/EBITDA of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBITDA growth rates and interactive chart. EV/EBITDA is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation & Amortization (EBITDA). The EV/EBITDA ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBITDA compared to a stock’s historical average or industry can indicate undervaluation.


Highlights and Quick Summary

Current EV/EBITDA of AbbVie Inc. is 10.53 (as of December 30, 2019)
  • EV/EBITDA for the quarter ending June 29, 2020 was 17.3 (a 95.1% increase compared to previous quarter)
  • Year-over-year quarterly EV/EBITDA increased by 5.54%
  • Annual EV/EBITDA for 2019 was 10.53 (a -50.78% decrease from previous year)
  • Annual EV/EBITDA for 2018 was 21.39 (a 27.98% increase from previous year)
  • Annual EV/EBITDA for 2017 was 16.72 (a 33.69% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBITDA of AbbVie Inc.

Most recent EV/EBITDAof ABBV including historical data for past 10 years.

Interactive Chart of EV/EBITDA of AbbVie Inc.

AbbVie Inc. EV/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 17.3 8.87
2019 10.53 16.39 15.59 18.22 10.53
2018 21.39 14.25 15.23 14.93 21.39
2017 16.72 14.96 13.09 12.52 16.72
2016 12.5 12.89 13.43 12.74 12.5
2015 14.28 19.52 27.34 22.42 14.28
2014 26.44 15.7 14.3 13.27 26.44
2013 13.53 10.97 10.05 10.12 13.53
2012 9.05 9.05 9.05 9.05 9.05
2011 9.05 9.05 9.05 9.05 9.05
2010 9.05
2009 9.05

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.